Ribavirin

Presented by :
• Shahd Diefalla 236025 Mohrael Yasser 232681
• Reham Gomaa 237899 Moamen Gaser 232557
• Radwa Mahmoud 236713 Ahmed Ahmed 238311

Presented to :
Dr.Amal
  Introduction

• Researchers from the International Chemical and Nuclear

Corporation (ICN), now known as Valeant Pharmaceuticals, made
the first discovery and development of ribavirin in 1970.

• Ribavirin was initially accepted for use in humans to treat viral

infections of the respiratory tract in young children. Ribavirin was
shown to be effective against DNA and RNA viruses in culture
systems and animals in 1972. Inducing a viral response and
lowering the frequency of viral relapse after stopping treatment
are both benefits of ribavirin.

• Ribavirin may, however, result in side effects that force an early

end to the course of therapy. The most prevalent of them is
hemolytic anaemia, which is brought on by an overabundance of
red blood cells.
 • Chemical structure
H N
2 O

• Chemical Formula:
N
N
C14H24N4O5
N

H O
O H

H O

• IUPAC nomenclature
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-
carboxamide
 • Types of bonds
𝞂 Double bond (𝞂-π )
H N
2 O
𝞂 Double bond (𝞂-π )
𝞂
N
N
Double bond (𝞂-π ) 𝞂
N
𝞂 𝞂
𝞂 O
𝞂
𝞂 H O
𝞂
O H

𝞂 𝞂 H O
𝞂
𝞂 𝞂
C-C non polar covalent bond
N-N non polar covalent bond 𝞂:sigma bond
C-N polar covalent bond π:pi bond
C-O polar covalent bond
 • Types of hybridization
sp2
H N
2
sp2 O

N sp2
N

sp3 O
sp3
H O
O H

H O

sp3
sp3 sp3
 • Mesomeric and
inductive effect
H N -M
+M 2
O

N
N -I
N

HO

OH

HO
• Reference
1. Thomas E, Ghany MG, Liang TJ. The application and
mechanism of action of ribavirin in therapy of hepatitis C.
Antiviral Chemistry and Chemotherapy. 2012 Aug;23(1):1-2.

2. MD Pauly, DM Lyons, WJ Fitzsimmons, AS Lauring -

MSphere, 2017 - Am Soc Microbiol.

3. Expert Committee:(PA7)Pharmaceutical Analysis 7

USP28–NF23Page 1722